Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Sarcomas are rare, heterogeneous cancers with limited effective treatments for advanced stages.
• Standard therapies often fall short, necessitating novel therapeutic strategies.
• Molecular and genetic profiling is crucial for personalized sarcoma treatment.

Purpose of the Study:

• To review the mechanisms, recent advances, and future strategies for targeted and immune-based therapies in sarcoma treatment.
• To highlight the potential of anti-angiogenesis, CDK4/6, PARP, IGF-1R, mTOR, NTRK, metabolic, and epigenetic inhibitors.
• To discuss the application and challenges of immunotherapies, including immune checkpoint inhibitors and cellular therapies.

Main Methods:

• Comprehensive literature review of targeted and immune-based therapies for sarcomas.
• Analysis of clinical trial data and preclinical research findings.
• Focus on molecular mechanisms, efficacy, and challenges of novel treatment modalities.

Main Results:

• Anti-angiogenesis therapy shows favorable efficacy in sarcomas.
• Various targeted therapy agents are under clinical evaluation for specific sarcoma subtypes.
• Immunotherapy, particularly cellular therapies, demonstrates therapeutic potential despite challenges with "cold" tumors.

Conclusions:

• Targeted therapies tailored to sarcoma's molecular profile are a promising avenue.
• Immunotherapy, including cellular approaches, holds significant potential but requires further research to overcome immune resistance.
• Addressing challenges in antigen identification and immune modulation is key to advancing sarcoma immunotherapy.